Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Net Income towards Common Stockholders (2016 - 2026)

Seres Therapeutics (MCRB) has disclosed Net Income towards Common Stockholders for 11 consecutive years, with $32.7 million as the latest value for Q1 2025.

  • Quarterly Net Income towards Common Stockholders rose 181.43% to $32.7 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $32.7 million through Dec 2025, down 51.08% year-over-year, with the annual reading at $125.9 million for FY2024, 64.79% up from the prior year.
  • Net Income towards Common Stockholders hit $32.7 million in Q1 2025 for Seres Therapeutics, down from $139.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $139.8 million in Q3 2024 to a low of -$71.2 million in Q1 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$15.8 million across 5 years, with a median of -$37.6 million in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 187.96% in 2022 and later skyrocketed 2144.32% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$50.0 million in 2021, then crashed by 37.59% to -$68.8 million in 2022, then surged by 90.51% to -$6.5 million in 2023, then skyrocketed by 2240.73% to $139.8 million in 2024, then crashed by 76.62% to $32.7 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for MCRB at $32.7 million in Q1 2025, $139.8 million in Q3 2024, and -$32.9 million in Q2 2024.